The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey.
The survey of 502 employers by Accolade, a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.
"For the 43% planning to offer coverage next year, we recommend a physician-led approach that guides who should be prescribed GLP-1 medications and how to make them part of a holistic health management plan," Accolade Associate Chief Medical Officer James Wantuck said. Employers that cover weight-loss drugs are facing a spike in their healthcare costs because of the growing popularity of Wegovy.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
U.S. employers covering weight-loss drugs could nearly double in 2024 - surveyU.S. employers covering weight-loss drugs could nearly double in 2024 - survey
Baca lebih lajut »
The Dark Side of Weight Loss Drugs: Startling New Risks RevealedScience, Space and Technology News 2023
Baca lebih lajut »
Weight-loss drug approved for use by NHS ScotlandWegovy, which is delivered via injection, makes people feel fuller and more satisfied so they eat less.
Baca lebih lajut »
Mauricio Umansky Reveals Weight Loss Transformation From Dancing With the Stars WorkoutsMauricio Umansky is looking a lot slimmer since joining Dancing With the Stars season 32. Find out just how much weight the Real Housewives star has lost since hitting the dance floor.
Baca lebih lajut »
UCLA Discovers Weight Loss Game-Changer: Stimulating Brown Fat To Fight ObesityScience, Space and Technology News 2023
Baca lebih lajut »
Focus: Weight-loss drugs fuel boom for firms that fill syringesContract drug manufacturers seeking to tap into the booming market for weight-loss drugs are investing billions of dollars to expand or build factories that fill the injection pens used to administer treatments like Novo Nordisk's (NOVOb.CO) Wegovy.
Baca lebih lajut »